April 23, 2024 02:14 PM EDT
Deals
Pharma
Manufacturing

Ver­tex li­cens­es TreeFrog’s tech to up­scale cell ther­a­py man­u­fac­tur­ing for di­a­betes can­di­dates

Anna Brown

News Reporter

Ver­tex will pay $25 mil­lion up­front for TreeFrog Ther­a­peu­tics’ cell man­u­fac­tur­ing tech­nol­o­gy that can help boost pro­duc­tion of its ear­ly-phase type 1 di­a­betes as­sets. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times